NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company developing autologous natural killer cell therapies, with lead programs targeting Alzheimer's disease and certain oncology indications. The company entered the public markets through a business combination with Graf Acquisition Corp. IV, a blank-check vehicle in the healthcare and biotechnology sector sponsored by Graf Acquisition LLC that conducted its initial public offering in 2021. Following completion of that transaction, NKGen filed an S-1/A registration statement amendment with the SEC on June 27, 2024, reflecting continued post-merger regulatory reporting obligations. For complete filing histories, sponsor profiles, and deal analytics on NKGN and the broader SPAC universe, sign up for full access at SpacDesk.